Jefferies Group LLC set a GBX 4,900 ($66.06) price objective on AstraZeneca plc (LON:AZN) in a research report sent to investors on Monday morning. The firm currently has a neutral rating on the biopharmaceutical company’s stock.
Several other research analysts have also commented on the stock. Liberum Capital lowered shares of AstraZeneca plc from a buy rating to a hold rating and lifted their price target for the company from GBX 4,800 ($64.72) to GBX 5,000 ($67.41) in a report on Thursday, September 14th. J P Morgan Chase & Co reaffirmed a neutral rating and issued a GBX 4,500 ($60.67) price target on shares of AstraZeneca plc in a report on Thursday, September 14th. Barclays PLC set a GBX 6,300 ($84.94) price target on shares of AstraZeneca plc and gave the company a buy rating in a report on Wednesday, September 13th. Citigroup Inc. set a GBX 6,000 ($80.90) price target on shares of AstraZeneca plc and gave the company a buy rating in a report on Wednesday, September 13th. Finally, Berenberg Bank reaffirmed a buy rating and issued a GBX 5,500 ($74.15) price target on shares of AstraZeneca plc in a report on Monday, September 11th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have given a buy rating to the company. AstraZeneca plc has a consensus rating of Hold and a consensus price target of GBX 5,041.09 ($67.97).
Shares of AstraZeneca plc (LON AZN) opened at 4768.50 on Monday. The stock’s 50 day moving average is GBX 4,574.46 and its 200 day moving average is GBX 4,884.61. The firm’s market cap is GBX 60.37 billion. AstraZeneca plc has a 52 week low of GBX 3,996.00 and a 52 week high of GBX 5,520.00.
COPYRIGHT VIOLATION NOTICE: “Jefferies Group LLC Analysts Give AstraZeneca plc (AZN) a GBX 4,900 Price Target” was originally posted by BBNS and is owned by of BBNS. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/jefferies-group-llc-analysts-give-astrazeneca-plc-azn-a-gbx-4900-price-target/1654999.html.
The company also recently declared a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were issued a dividend of GBX 68.90 ($0.93) per share. The ex-dividend date was Thursday, August 10th. This represents a dividend yield of 1.35%.
In other news, insider Nazneen Rahman purchased 39 shares of the business’s stock in a transaction dated Thursday, July 27th. The shares were acquired at an average price of GBX 4,370 ($58.92) per share, for a total transaction of £1,704.30 ($2,297.83).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with our FREE daily email newsletter.